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Summary
Transthyretin amyloidosis (ATTR amyloidosis) is a disease
caused by deposition of transthyretin fibrils in organs and
tissues, which causes their dysfunction. The clinical het-
erogeneity of ATTR amyloidosis and the variable presen-
tation of symptoms at early disease stages, historically
meant treatment delays. Diagnostic tools and therapy op-
tions of ATTR amyloidosis have markedly improved in re-
cent years.
The first Swiss Amyloidosis Network (SAN) meeting
(Zurich, Switzerland, January 2020) aimed to define a con-
sensus statement regarding the diagnostic work-up and
treatment for systemic amyloidosis, tailored to the Swiss
healthcare system. A consortium of 45 clinicians and re-
searchers from all Swiss regions and universities was se-
lected by the SAN committee to represent all sub-special-
ty groups involved in care of patients with amyloidosis.
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analysis, wrote the critical synthesis and elaborated a list
of statements that were evaluated by all the participants.
These recommendations will improve outcomes and qual-
ity of life for patients with ATTR amyloidosis. A global re-
view of these guidelines is planned every 3 years with a
formal meeting of all the involved experts.
Introduction
These guidelines were written after an extensive literature
search using MedLine publications from January 1980 to
April 2021, under the terms “ATTR” AND “transthyretin”
AND “amyloidosis”. Only full articles in English were
considered. Following the literature search and review, the
steering committee developed a summary of relevant state-
ments that were evaluated by all the participants. Con-
sensus was established using online, single point-per-point
voting, through a nominal group technique. The level of
evidence and the strength of recommendation for specific
management options were weighed and graded according
to predefined scales, as outlined in tables 1 and 2.
The final guidelines were reviewed according to the Ap-
praisal of Guidelines for Research and Evaluation
(AGREE) II tool, to guarantee methodological rigour and
transparency. A summary of the resulting recommenda-
tions is presented in table 3.
Definition of transthyretin amyloidosis
Systemic amyloidosis is a term for a rare and underdiag-
nosed group of diseases, characterised by progressive tis-
sue infiltration of insoluble fibrillary proteins, derived
from a misfolded precursor protein, which normally cir-
culates in blood as a constituent of plasma [1]. The pre-
cursor protein defines the amyloid subtype and the asso-
ciated clinical manifestations. Free immunoglobulin light
chains and variant or wild-type transthyretin (TTR) are
the main amyloidogenic precursor proteins, causing light-
chain (AL) amyloidosis, and transthyretin (ATTR) amyloi-
dosis, respectively [1–3].
ATTR amyloidosis can be subdivided based on the
transthyretin protein involved, wild-type or variant (fig. 1)
[1–3]. Even though ATTR amyloidosis is a rare disease, its
prevalence is higher than current data suggest, in particu-
lar, cases with predominantly cardiac involvement, due to
wild-type ATTR deposition [4-7]. According to an analysis
of Centers for Medicare and Medicaid Services data, the
prevalence of cardiac ATTR amyloidosis increased from
18 to 55 per 100,000 between 2000 and 2012, likely due to
growing awareness and improved diagnostics, rather than
due to an actual increase in prevalence [8]. It can be ex-
pected that the number of patients being diagnosed with
cardiac ATTR amyloidosis will continue to rise in the fu-
ture.
Delays in the diagnosis of ATTR amyloidosis remain com-
mon, likely because of: the perceived rarity of the disease,
clinical heterogeneity, scarcity of centres and specialists
dedicated to disease management and, ultimately, equivo-
cal histological diagnosis.
Pathophysiology of transthyretin amyloidosis
Transthyretin (TTR), also known as prealbumin, is a 127
amino acid soluble and typically non-glycosylated protein,
mainly synthesised and secreted by hepatocytes in the liv-
Figure 1: Schematic representation of different types of
transthyretin amyloidosis. ATTR: transthyretin amyloidosis; ATTRv:





I Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective. Is recommended
II Conflicting evidence and/or a divergence of opinion about usefulness/efficacy of the given treatment or procedure.
IIa Weight of evidence/opinion is in favour of usefulness/efficacy. Should be considered
IIb Usefulness/efficacy is less well established by evidence/opinion. May be considered





Level of evidence Definition
A Data derived from multiple randomised clinical trials or meta-analyses.
B Data derived from a single randomised clinical trial or large nonrandomised studies.
C Consensus of opinion of the experts and/or small studies, retrospective studies, registries.
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er, the choroid plexus ependymal cells (in the brain) and
retinal epithelium (in the eye) [9]. TTR binds to retinol-
binding protein, which is involved in vitamin A transport.
TTR is also responsible for the transport of thyroxine (T4)
in plasma and cerebrospinal fluid (CSF), and circulates as
a tetramer [10].
In both wild-type ATTR amyloidosis (ATTRwt), formerly
known as "senile" systemic amyloidosis, and in the hered-
itary form, known as variant ATTR amyloidosis (ATTRv),
the disease is a consequence of transthyretin tetramer dis-
sociation into folded monomers, which then undergo con-
formational changes, leading to the formation of non-na-
tive oligomers and amyloid fibrils [11]. Truncated
C-terminal fragments can initiate aggregation and fibril-
logenesis from either unstable variants or wild-type TTR
[12]. This mechanism is promoted by mechanical shear
stress, in combination with hydrophobic forces generated
by extracellular matrix components (such as serum amy-
loid P and glycosaminoglycans) [12], and also involves
proteostasis processes, which misfold and aggregate pro-
teins [13, 14]. Amyloid-related tissue changes can be dis-
played as mechanical disarrangement, disruption of cell
membrane integrity, inflammatory reactions, hypoxic cell
Table 3:
Summary of Swiss Amyloidosis Network (SAN) recommendations.
Recommendation Level
Hereditary transthyretin amyloidosis (ATTRv)
A comprehensive initial work-up in a centre experienced in diagnosis and treatment of patients with ATTRv amyloidosis is recommended. I, C
A low threshold for genetic testing in patients with suspected ATTRv amyloidosis is recommended. I, C
A biopsy of the organ mainly involved, the gastrointestinal tract, the accessory salivary glands or an abdominal fat aspirate for detection of amy-
loid should be considered in suspected systemic ATTR amyloidosis.
IIa, C
For patients with systemic ATTR amyloidosis, TTR amyloid detection and characterisation in one anatomical site is sufficient to make the diagnosis. I, C
A positive bone scintigraphy (Perugini score grade 2 or higher) can substitute tissue biopsy for diagnosing ATTRv amyloidosis with cardiac involve-
ment in the absence of concomitant monoclonal gammopathy, but false negative results can occur.
I, B
Genetic counselling for all patients with hereditary amyloidosis is recommended I, C
Genetic counselling should be coordinated by amyloidosis specialists together with a certified genetic counselling centre. I, C
Pre-symptomatic testing should be considered. IIa, C
Cardiac and neurological staging of all patients with ATTRv amyloidosis is recommended. I, B
Disease-modifying treatment is recommended according to current drug approval status in Switzerland. I, B
Liver transplantation should be considered as second-line treatment option for patients with early-onset ATTRv amyloidosis with a primarily neuro-
logical phenotype and RNAi; patisiran, Onpattro®) treatment failure or intolerance.
IIa, C
Heart transplantation should be considered as an option for younger patients with predominant and advanced cardiac involvement not responding to
disease-modifying drugs, or for whom disease-modifying drugs are not available or unlikely to be effective
IIa, C
Clinical and biological follow-up in specialised centres every 3–6 months is recommended, including a comprehensive follow-up with disability and
QOL questionnaires, and a standardised cardiological and neurological work-up
I, C
A standardised ophthalmological assessment is recommended every 1–2 years. I, C
SAN recommends that the lead for patient follow-up should be cardiological for patients with predominantly cardiac manifestations, and neurological
for patients with predominantly neurological manifestations.
I, C
Wild-type transthyretin amyloidosis (ATTRwt)
Interdisciplinary discussion of the results obtained during the screening for monoclonal gammopathy with specialists in haemato-oncology should be
considered.
IIa, C
The following screening panel for monoclonal gammopathy should be considered: serum protein electrophoresis, serum immunofixation, serum free
light chain measurement and urine immunofixation.
IIa, B
TTR genetic testing should be considered in all patients with cardiac ATTR amyloidosis regardless of patient age. IIa, C
A visit to a neurologist may be considered at baseline for patients with ATTRwt amyloidosis and neuropathy. IIb, C
A cardiological work-up is recommended at baseline, including ECG, 24-hour ECG, blood pressure and TTE. The need for bone scintigraphy, car-
diac MRI and myocardial biopsy should be discussed by an interdisciplinary team on a case-by-case basis.
I, B
Initial staging of all patients with ATTRwt amyloidosis should be considered. IIa, B
SAN recommends treatment guided by experienced centres, using a multidisciplinary approach (cardiology, haemato-oncology, neurology, nephrolo-
gy, gastroenterology).
I, C
Treatment with tafamidis 61 mg should be considered for patients with cardiac ATTRwt amyloidosis and dyspnoea NYHA class I–III IIa, B
Case-by-case discussions should be considered prior to tafamidis initiation for patients with significant comorbidities that interfere with intermediate-
term survival.
IIa, C
Case-by-case discussions should be considered for patients with complex cardiac situations (e.g., concomitant aortic stenosis, concomitant severe
coronary artery disease), patients with a formal indication for implantation of an internal cardioverter defibrillator, and patients with typical angina due
to microvascular disease
IIa, C
Cardiological follow-up should be considered every 3–6-months, including clinical and laboratory evaluation (NT-proBNP, troponin T, creatinine, pro-
teinuria, albuminuria), and a comprehensive evaluation including ECG, 24-hour ECG, TTE every 612 months, ergometry, depending on disease
severity and treatment.
IIa, C
Regular blood pressure and body weight home monitoring may be considered in order to adapt diuretic dose targeting euvolaemia IIb, C
Patients at risk for developing systemic ATTR amyloidosis
Asymptomatic carriers: based on the specific TTR mutation and the onset age in other affected family members, PADO can be estimated. Systemic
monitoring of asymptomatic carriers should be considered at least 10 years prior to PADO
IIa, C
Domino Liver TPL: 6-monthly or yearly follow-up for signs of neuropathy (including BMI, autonomic dysfunction) should be considered. IIa, B
ATTR in tissue biopsies (lumbar spine, CTS, etc.):a cardiac work-up including ECG, TTE (including speckle-tracking echocardiography based left
ventricular strain analysis) and genetic testing for ATTRv amyloidosis should be considered
IIa, C
ATTRv amyloidosis: variant transthyretin amyloidosis; ATTRwt amyloidosis: wild-type transthyretin amyloidosis; ATTRv: variant transthyretin amyloidosis; BMI: body mass index;
ECG: electrocardiography; CTS: carpal tunnel syndrome; NYHA: New York Heart Association; NT-proBNP: N-terminal pro-B-type natriuretic peptid; MRI: magnetic resonance
imaging; PADO: predicted age at disease onset; QOL: quality of life; RNAi: RNA interference; TPL: transplantation; TTE: transthoracic echocardiography; TTR: transthyretin.
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damage and/or alteration of the structure of the extracellu-
lar matrix [14, 15].
Incidence/prevalence of transthyretin amyloidosis
Depending on the absence or presence of a pathogenic
transthyretin mutation, ATTR amyloidosis can be further
subdivided into ATTR amyloidosis caused by deposits of
the wild-type TTR protein (ATTRwt), and ATTR amyloi-
dosis caused by a genetically determined variant TTR pro-
tein (ATTRv).
Overall, ATTRv amyloidosis is a rare disease, with a glob-
al prevalence of 1:1,000,000 people [16, 17], though it is
endemic in certain areas of Portugal, Japan, Sweden and
Brazil, where the prevalence may be as high as 1:1000 [16,
17].
ATTRwt amyloidosis is more common than ATTRv amy-
loidosis, although the true prevalence is unknown. Amy-
loid is formed by wild-type TTR deposits in the heart
and ligaments during aging, particularly in male subjects
[18, 19]. The reason(s) behind the observed tissue tropism
and gender difference are not yet clear. In autopsy studies,
≈25% of people at least 80 years old had wild-type TTR
fibrils in their hearts, regardless of the presence of symp-
toms [19, 20]. Studies using non-biopsy diagnostic ap-
proaches demonstrated TTR prevalences of 10–13%
among patients undergoing percutaneous aortic valve re-
placement for severe aortic stenosis, 13% among patients
with heart failure with preserved ejection fraction (HFpEF)
and 5% among patients with presumed hypertrophic car-
diomyopathy [5, 7, 21–23]. About 60% of patients with
ATTR amyloidosis have a personal history of carpal tunnel
syndrome, and 5–14% have a personal history of lumbar
spinal stenosis [24]. The prevalence of ATTR in tissue
biopsies from unselected patients with lumbar spinal steno-
sis is as high as 38.5%, and is 10.2% in patients with
bilateral carpal tunnel syndrome [25, 26]. Most of these
patients do not have systemic ATTR amyloidosis with car-
diac and/or neurological involvement at the time of
surgery, and the percentage of patients who will eventually
progress and develop systemic ATTR amyloidosis is not
yet known.
Clinical presentation of transthyretin amyloidosis
The main clinical features of ATTR amyloidosis are car-
diomyopathy and neuropathy.
ATTRwt amyloidosis usually presents as heart failure (HF-
pEF) in elderly male patients, but bilateral carpal tunnel
syndrome, lumbar spinal stenosis and biceps tendon rup-
ture can precede the onset of cardiac symptoms by a
decade or more [24]. In ATTRwt amyloidosis, peripheral
and autonomic neuropathy manifestations are less severe
than in ATTRv amyloidosis (table 4).
ATTRv amyloidosis usually presents as peripheral small-
fibre polyneuropathy with dysautonomia, but can also
manifest as a primary cardiomyopathy, depending on the
genotype (see section 2 and fig. 2) [3]. The natural history
of ATTRv amyloidosis, including age of onset, phenotype
and clinical course varies with: mutation, fibril type (full
length vs fragments) and within families and/or regions.
Diagnosis of ATTRv amyloidosis neuropathy is usually
straight-forward where the disease is endemic (Portugal,
Japan, Sweden, Brazil), thanks to higher awareness, typical
phenotype and known family history. In non-endemic ar-
eas, where ATTRv amyloidosis is rare and mostly presents
as a late-onset disease, the diagnosis can be challenging.
Unexplained sensorimotor neuropathy or autonomic symp-
toms (orthostatic dysfunction, erectile dysfunction, sweat-
ing abnormalities, unexplained weight loss and diarrhoea),
are typical but unspecific symptoms of ATTRv amyloido-
sis, and may delay diagnosis [27].
Objectives of the initial assessment of a patient with
suspected transthyretin amyloidosis
The main objective of the initial assessment is to confirm
the diagnosis and rule out other amyloidosis subtypes,
mainly light-chain amyloidosis. Once a diagnosis of ATTR
amyloidosis is made, some of the main tasks of a compre-
hensive amyloidosis management are: determination of the
extent of systemic involvement (staging); treatment indi-
cation and strategy; definition of follow-up intervals and
tests; education of patients and their families (including
genetic counselling for ATTRv amyloidosis).
Figure 2: Correlations between genotype and phenotype in variant
transthyretin amyloidosis. ATTR: transthyretin amyloidosis.
Table 4:
Main clinical characteristics of ATTRv and ATTRwt amyloidosis.
ATTRv amyloidosis ATTRwt amyloidosis
Prevalence <1:100000 Unknown
Age at presentation Variable >60 years
Gender prevalence Male Male
Common disease manifestation Polyneuropathy Heart
Carpal tunnel syndrome Extracardiac involvement: Carpal tunnel syndrome
Dysautonomia Lumbar spinal stenosis
Eye involvement Biceps tendon rupture
ATTRv amyloidosis: variant transthyretin amyloidosis; ATTRwt amyloidosis: wild-type transthyretin amyloidosis.
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At diagnosis, each patient should undergo a complete eval-
uation of organ involvement. The cardiac evaluation in-
cludes: functional class, fluid balance, orthostatic function
and heart rhythm. Assessment of the nervous system in-
cludes: functional capacity, quantification of nerve dam-
age, assessment of autonomic dysfunction (including gas-
trointestinal and urogenital systems) and weight changes.
Renal function should be assessed (estimated glomerular
filtration rate [eGFR], albuminuria, proteinuria), as should
the eyes (keratoconjunctivitis sicca, vitreal deposits, sec-
ondary glaucoma or retinal angiopathy) [6].
Hereditary transthyretin amyloidosis (ATTRv)
ATTRv amyloidosis is an autosomal-dominant disease
with variable penetrance. Based on the underlying muta-
tion in the TTR gene, ATTRv amyloidosis can present as
predominantly neurological or predominantly cardiologi-
cal disease, although cardiomyopathy and polyneuropathy
manifestations may coexist (fig. 2).
The most common TTR mutation, p.V142I (also known as
“V122I”), occurs mainly as cardiomyopathy in 3–10% of
black Americans older than 60 years, with undefined phe-
notypic penetrance [28].
The p.V50M (also known as “V30M”) mutation is the
most common and prototypical form of amyloid polyneu-
ropathy. Two different clinical forms called "early-onset",
and "late-onset" ATTRv related to p.V50M can be distin-
guished.
Early-onset p.V50M: Early-onset ATTRv amyloidosis usu-
ally presents in Portuguese and Japanese patients under 50
years of age, with a peak between the ages of 25 and 35
years. Initial symptoms include paraesthesia of the lower
limbs (40%), neuropathic pain (5%), autonomic dysfunc-
tion with diarrhoea and/or constipation (40%), erectile dys-
function (9%), hypotension and unexplained weight loss
(16% at presentation) [29–32]. With advancing disease,
the involvement of large-diameter nerve fibres eventually
manifests with impairment of all sensory modalities and
motor dysfunction, with progressive walking imbalance
until a wheelchair in needed [29–32]. Without disease-
modifying treatment, the mean survival time of early-onset
ATTRv amyloidosis ranges from 10 to 15 years from diag-
nosis [33].
Late-onset p.V50M: Late-onset ATTRv amyloidosis is
more common in central Europe and Sweden and usually
affects individuals (mostly men) older than 50 years of
age, with a positive family history in 50–60% of cases [32,
34]. The median delay to diagnosis is 3 years, likely be-
cause of the clinical phenotype variability. Sensorimotor
symptoms can begin distally, in the lower extremities, with
disturbance of both superficial and deep sensation [29,
32]. However, a great proportion of patients present with
symptoms mimicking other forms of peripheral neuropa-
thy (upper limb onset neuropathy, ataxic neuropathy, mul-
tiplex neuritis and motor neuropathy) [35–37]. Autonomic
dysfunction is usually milder than in early-onset patients,
whereas neuropathic pain is present in almost 50% of the
patients. The rate of neuropathy progression is higher than
in early-onset cases [38, 39]. The most common misdi-
agnoses are chronic inflammatory demyelinating polyneu-
ropathy followed by idiopathic axonal polyneuropathy and
lumbar canal stenosis [40, 41]. Cardiomyopathy may also
occur.
Additional differences between early-onset and late-onset
p.V50M include a higher rate of renal involvement, with
proteinuria and progressive renal failure in the former and
a significant association with bilateral carpal tunnel syn-
drome in the latter. Atrioventricular conduction blocks re-
quiring pace-maker implantation are very common in ear-
ly-onset p.V50M. Biochemically, amyloid fibrils consist of
only full-length TTR in early-onset patients’ tissues, and
of both C-terminal fragmented and full-length TTR in late-
onset cases [42].
Outside endemic areas, disease clusters have been reported
in many other countries, mainly related to migratory move-
ments [34].
Diagnosis
A comprehensive initial work-up in a centre experienced in
diagnosis and treatment of patients with ATTRv amyloido-
sis is recommended (table 5) [I, C]. The initial work-up
aims at securing the diagnosis and provides the basis for
treatment indication, and for treatment response assess-
ments.
A low threshold for genetic testing in patients with suspect-
ed ATTRv amyloidosis is recommended [I, C]. Cost cov-
erage for genetic testing by the healthcare insurance is
granted either under the position for amyloidotic polyneu-
ropathy or under the "orphan disease" provisions in the
case of non-neurological manifestations. For the latter, a
request for coverage has to be obtained from the health
insurance beforehand, which we also recommend for the
amyloidotic polyneuropathy provisions, although it is not
mandatory there.
Suspicion of ATTRv amyloidosis should be high for pa-
tients with progressive idiopathic, axonal polyneuropathy
(i.e., affecting temperature and pain sensation), or atypical
chronic inflammatory demyelinating polyneuropathy, es-
pecially if refractory to treatment, particularly in elderly
patients who also present with symptoms of systemic in-
volvement, even in the absence of a suggestive family
history [27]. For patients with a known family history
of ATTRv amyloidosis, any onset of any type of axonal
polyneuropathy, autonomic dysfunction or cardiac arrhyth-
mia warrants an assessment for organ involvement. Of
note, individuals with a known family history may be of-
fered presymptomatic testing, and should be regularly fol-
lowed to detect amyloidosis onset (see sections 2.2.3 and
4.1).
Initial work-up
Initial work-up in ATTRv amyloidosis aims at confirming
amyloid deposits with a tissue biopsy (gastrointestinal,
salivary gland, skin, peripheral nerve, heart), including
typing of the amyloid by immunohistochemistry or spec-
trometry, and screening for TTR mutations by TTR gene
sequencing. In the absence of monoclonal gammopathy,
scintigraphy using bone-avid radiotracers can diagnose
ATTR amyloidosis with cardiac involvement without the
need for biopsies, but false negative scintigraphy results
can occur, especially in patients with cardiac ATTRv amy-
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loidosis (see section 3.1.1). In a second step, the extent of
organ involvement has to be determined.
Personal and family history
During the initial assessment, autonomic dysfunction, gait
disorders, gastrointestinal disorders, weight loss, carpal
tunnel syndrome or previous surgery for bilateral carpal
tunnel syndrome, and concurrent cardiac abnormalities
should be checked. A detailed family history for ATTRv
must be obtained, and any severe neuropathy of a family
member, especially when leading to death within a few
years of symptom onset, should raise suspicion for ATTRv
[43, 44].
Tissue biopsy for amyloid detection and laboratory testing
A biopsy of the main involved organ, the gastrointestinal
tract, the accessory salivary glands or an abdominal fat
aspirate for amyloid detection should be considered in sus-
pected systemic ATTR amyloidosis [ IIa, C]. Skin biopsy
can be useful in centres experienced in amyloid detection
in ATTRv amyloidosis with mainly neurological manifesta-
tions. For patients with systemic ATTR amyloidosis, TTR
amyloid detection and characterisation in one anatomical
site is sufficient to make the diagnosis [ I, C]. A positive
bone scintigraphy (Perugini score grade 2 or higher) can
substitute tissue biopsy for diagnosing ATTRv amyloido-
sis with cardiac involvement in the absence of concomitant
monoclonal gammopathy, but false negative results can oc-
cur [I, B].
Staining of biopsy samples with Congo red and visuali-
sation of atypical colours (green, yellow or orange bire-
fringence) under polarised light is indicative of the pres-
ence of amyloid fibrils. Once Congo red-positive material
is detected, the subtype of amyloid has to be determined
by immunohistochemistry, and if immunohistochemistry
is inconclusive, by mass spectrometry or immunoelectron
microscopy [6, 27, 45–47].
Amyloid infiltration can be demonstrated in tissue samples
taken from a surrogate site (e.g., abdominal fat pad, sali-
vary glands or rectum), or from a clinically involved organ.
Accessory salivary gland biopsy has a sensitivity of 75%
for amyloid detection in patients with ATTRv amyloidosis
when performed in an experienced centre [48]. Sural nerve
biopsy is performed only occasionally, mostly to rule out
differential diagnoses. It is always recommended to ask for
past biopsies (most often gastrointestinal), when available,
to be tested for amyloid deposits.
Detection of amyloid deposits can be challenging, and neg-
ative biopsy results should not rule out the diagnosis. Re-
peated tissue biopsy may be required (see section 3.1) [49].
In one study, ATTR amyloid was detectable in 27.3% of
abdominal fat aspirates. ATTR amyloid deposits were de-
tected in 35.4% of bone marrow biopsies and 33.3% of
gastrointestinal biopsies when abdominal fat aspiration
was not able to provide evidence of amyloid [50]. When
ATTR amyloid was detectable in abdominal fat aspirates, it
was also detectable in 66.6% of bone marrow and 68.2% of
gastrointestinal biopsies. The sensitivity of screening biop-
sies is lower in patients with ATTR amyloidosis than in
those with AL amyloidosis [50].
A blood test should include at least complete blood count,
creatinine, eGFR, liver values including alkaline phos-
phatase, N-terminal pro-B-type natriuretic peptide (NT-
proBNP), troponin T, serum protein, albumin, prealbumin,
albuminuria, proteinuria, serum free light chains, and
serum and urine protein electrophoresis with immunofix-
ation. Further tests such as thyroid stimulating hormone
(TSH) / free thyroxine (fT4), iron status, vitamin B12 and
screening for diabetes mellitus should be performed to rule
out concomitant diagnoses affecting the nervous system.
Genetic testing, pre-symptomatic testing and genetic
counselling
SAN recommends genetic counselling for all patients with
hereditary amyloidosis [I, C]. Genetic testing should be
offered to all symptomatic relatives, and discussed indi-
vidually with asymptomatic relatives, starting with the pa-
tient’s siblings. Genetic counselling should be coordinated
by amyloidosis specialists together with a certified genetic
counselling centre [I, C].
Pre-symptomatic testing should be considered [ IIa, C].
Since the application on 1 April 2007 of the Law on Hu-
man Genetic Analysis (GUMG /LAGH), genetic coun-
selling and informed consent are formally required before
any genetic testing and should be performed by dedicated
centres. A list of Swiss genetic counselling centres can be
found on the homepage of the Swiss Society of Medical Ge-
netics (www.sgmg.ch). Cost coverage of genetic testing for
symptomatic patients by the healthcare insurance is either
under the provisions for amyloidotic polyneuropathy, or in
the case of non-neurological manifestations under the or-
phan disease provisions. For the latter, a request for cov-
erage has to be obtained from the health insurance be-
forehand, which we also recommend for the amyloidotic
polyneuropathy provisions, although not mandatory there.
Considering the short length of the TTR gene, and the lim-
ited number of coding exons (3 exons), genetic investiga-
tion of pathological mutations associated with hereditary
forms of systemic amyloidosis can be performed by Sanger
sequencing. An updated list of all amyloidogenic muta-
tions identified so far is available on www.amyloidosismu-
tations.com [51]. There are few non-amyloidogenic muta-
tions.
The increasing availability of effective and early treat-
ments led to the promotion of pre-symptomatic testing for
hereditary TTR amyloidosis, with differing counselling
protocols among countries [52, 53].
Especially in endemic areas for early-onset ATTRv amy-
loidosis, harbouring a TTR mutation might entail decisions
about reproduction (including the choice of prenatal or
pre-implant diagnosis, depending on the respective legal
premises), with a psychological impact that warrants ad-
equate support [54, 55]. Overall, pre-symptomatic testing
for ATTRv amyloidosis appears to be feasible when per-
formed within a multidisciplinary team. Family investiga-
tion sometimes contributes to identifying affected family
members.
Given the increasing availability of therapeutic options,
how best to monitor mutation carriers and when to initiate
treatment is currently a debated topic (see section 4.1.).
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Neurological work-up
A comprehensive neurological assessment for ATTRv
amyloidosis requires time and resources. It includes stan-
dardised questionnaires, a complete personal and family
history, and a systematic clinical work-up for sensory, au-
tonomic and motor neuropathy. Table 6 summarises the
recommended initial neurological work-up for specialised
neurological centres caring for patients with ATTRv amy-
loidosis. Standardised baseline assessments and follow-up
visits not only guarantee quality of patient care, but are
needed for regulatory reasons in patients receiving disease-
modifying drugs. Recommendations for initial and period-
ic assessments are summarised in tables 5 and 6.
Nerve conduction study
A nerve conduction study is mandatory to evaluate periph-
eral neuropathy, usually demonstrating symmetrical axon-
al sensorimotor polyneuropathy in patients with ATTRv
amyloidosis [56, 57]. Of note, if done early in the disease
course, the nerve conduction study can be normal since up
to 5% of patients with ATTR amyloidosis have involve-
ment of only unmyelinated C-fibres [58]. The nerve con-
duction study can also show demyelinating features with
slowing of conduction velocity and prolonged distal motor
latencies leading to a misdiagnosis of chronic inflamma-
tory demyelinating polyneuropathy. The composite nerve
conduction score should be calculated at baseline and fol-
low-up [59]. Autonomic function can be assessed with
sympathetic skin response and R-R interval.
Small fibre assessment
Detection of small fibre involvement starts with specific
questionnaires (SFN S1Q, see table 5) and clinical exami-
nation, looking for pain and loss of sensation of tempera-
ture. Clinical examination can be completed with quantita-
tive tests (Sudoscan® for sudomotor function, quantitative
sensory testing), when available. The gold standard for di-
agnosing small fibre neuropathy is quantification of intra-
epidermal nerve fibres in a skin biopsy (70–90% sensi-
tivity and specificity) [60, 61]. However, skin biopsy is
usually not necessary to diagnose small fibre neuropathy in
patients with ATTR amyloidosis, unless it is also used for
Table 5:
Recommendations for baseline and follow-up assessment of patients with ATTRv amyloidosis.
Tool Baseline 3–6 monthly 12 monthly
General health assess-
ment
Patient history, physical examination, standard laboratory testing X X X
Weight X X X
Conventional BMI X X X
Modified BMI X X X
Albumin X X X
Prealbumin X X X
Medication Check for completeness, interactions, harmful prescriptions X X X
Neurology Norfolk QOL X X X
Compass 31 or CADT X X X
SFN S1Q X X X
RODS X X X
Schellong X X X
Composite nerve conduction score X - X
Sudoscan X - X
Grip test X - X
NIS LL and UL X X X
PND and FAP stage X X X
Cardiology NT-proBNP X X X
ECG X X X
24-hour ECG X X for cardiac ATTR X for cardiac ATTR
TTE X X for cardiac ATTR X for cardiac ATTR
CMR X - (consider repeating at 2 years)
6-min walking test X X X
Scintigraphy using bone-avid radiotracers (X) discuss case-by-case - -
NYHA class X X X
Nephrology Serum creatinine/eGFR X X X
Urine creatinine/protein/albumin X
Sonography X - -
Ophthalmology Visual acuity, check for amyloid deposits X - X
Gastroenterology Ask for early satiety, postprandial fullness, nausea, vomiting and
weight loss
Endoscopy, oesophageal and intestinal manometry, and gastric emptying studies if
symptomatic
Ask about constipation, diarrhoea, incontinence Endoscopy, search for bacterial overgrowth, bile acid and fat malabsorption if
symptomatic
Alkaline phosphatase X X X
Abdominal sonography X - -
Psychology/social ser-
vice
Check if support needed X X X
ATTRv: variant transthyretin amyloidosis; COMPASS score: composite autonomic symptom score; NIS-LL and -UL: neuropathy impairment score in the lower limbs and upper
limbs; PND score: polyneuropathy disability score; QOL: quality of life; RODS questionnaire: Rasch‐built overall disability scale questionnaire; SNF SIQ: small fibre neuropathy
symptom inventory questionnaire.
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amyloid detection and characterisation (this approach re-
quires expertise and is only possible in few centres).
Cardiological work-up
A minimal cardiac baseline assessment should include
blood pressure, Schellong test, electrocardiography (ECG),
24-hour ECG, exercise test and/or 6-minute walking test,
transthoracic echocardiography (TTE) including speckle-
tracking echocardiography based left ventricular deforma-
tion analysis (global longitudinal strain), and/or cardiac
magnetic resonance imaging (CMR) [62, 63]. The indica-
tion for bone scintigraphy is discussed in detail in section
3.1. In general, ATTR amyloidosis with cardiac involve-
ment can be assessed without the need of biopsies, with
scintigraphy using bone-avid radiotracers. Evidence-based
data demonstrate that bone scintigraphy using technetium-
labelled radiotracers provides very high diagnostic accura-
cy in the non-invasive assessment of cardiac ATTR [64].
However, the sensitivity of bone scintigraphy may be low-
er in ATTRv amyloidosis than in ATTRwt amyloidosis,
depending on the type of mutation [65–68]. As recently
reported and for reasons still unknown, patients with ear-
ly-onset p.V50M and the p.F84L (also known as “F64L”)
variant do not show cardiac tracer uptake [69, 70].
Initial staging and risk stratification
SAN recommends cardiac and neurological staging of all
patients with ATTRv amyloidosis [I, B].
Cardiac biomarkers, estimated glomerular filtration rate
and functional class according to the New York Heart As-
sociation (NYHA) have been extensively studied to define
prognosis in cardiac ATTR amyloidosis [71–74] (tables 7
and 8).
The neurological stage should be determined according to
the transthyretin familial amyloid polyneuropathy (TTR-
FAP; Coutinho) staging system and the peripheral neu-
ropathy disability (PND) score (table 9) [75, 76].
Treatment
SAN recommends disease-modifying treatment according
to current drug approval status in Switzerland [I, B].
ATTRv amyloidosis with neurological manifestations:
Patisiran (Onpattro ® ) monotherapy has received mar-
keting authorisation, and is approved for the treatment of
symptomatic, primarily neurological patients with hered-
itary transthyretin-mediated amyloidosis (ATTRv) with a
PND stage ≥I and ≤IIIb, or a TTR-FAP stage >0 and ≤2,
and with an initial NIS-LL between 5 and 130. One of
the two designated Swiss ATTRv treatment centres (CHUV,
Lausanne and University Hospital Zurich) must apply for
reimbursement, initiate and follow up treatment for all
Swiss patients. Patients are required to have a life ex-
pectancy of >2 years and NYHA functional class II or low-
er. Patients have to be included in a designated registry.
Reimbursement of patisiran for treatment initiation and
continuation is regulated in detail by the Federal Office of
Public Health (FOPH, list of specialties).
Exclusively cardiac ATTRv amyloidosis (not qualifying for
patisiran): Tafamidis (Vyndaqel ® ) has received marketing
authorisation in Switzerland for the treatment of
transthyretin amyloidosis in adult patients with wild-type
or hereditary cardiomyopathy, but is not yet reimbursed. A
reimbursement request has to be approved by the health-
care insurance prior to treatment initiation. The requests
are currently evaluated according to article 71b KVV.
Table 7:
Clinical stages of cardiac ATTR.
eGFR (ml/min/1.73m 2 ) NT-pro BNP (ng/l)
Stage I ≥45 <3000
Stage II ≥45 >3000
<45 <3000
Stage III <45 >3000
ATTR: transthyretin amyloidosis; eGFR: estimated glomerular filtration rate: NT-pro BNP: N-terminal pro-B-type natriuretic peptide
Table 8:
New York Heart Association (NYHA) functional classification.
Stage Symptoms
I No limitations of physical activity. Normal physical activity does not cause symptoms of heart failure.
II Slight limitations of physical activity. Comfortable at rest, but normal physical activity leads to symptoms of heart failure.
III Moderate limitations of physical activity. Comfortable at rest, but less than normal physical activity leads to symptoms or heart failure.
IV Unable to carry out any physical activity without symptoms of heart failure, or symptoms of heart failure at rest.
Table 9:
TTR-FAP stage and peripheral neuropathy disability (PND) score.
TTR-FAP stage Symptoms PND
Stage 0 Asymptomatic -
Stage I Mild, ambulatory, symptoms at lower limbs limited I sensory disturbance (LL/UL), preserved walking capacity
II walking difficulties but no need for walking aid
Stage II Moderate, further neuropathic deterioration, ambulatory but requires
assistance
IIIa One stick or one crutch required for walking
IIIb Two sticks or two crutches required for walking
Stage III Severe, bedridden, bound to wheelchair, generalized weakness IV confined to wheelchair or bed
LL: lower limbs; TTR-FAP: transthyretin familial amyloid polyneuropathy; UL: upper limbs
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Liver transplantation should be considered as a second-
line treatment option for patients with early-onset ATTRv
amyloidosis with a primarily neurological phenotype and
RNAi (patisiran, Onpattro ® ) treatment failure or intoler-
ance [IIa, C].
Heart transplantation should be considered as an option
for younger patients with predominant and advanced car-
diac involvement not responding to disease-modifying
drugs, or for whom disease-modifying drugs are not avail-
able or unlikely to be effective [IIa, C].
Disease-modifying treatment
The aim of a disease-modifying treatment is to halt protein
aggregation and amyloid formation and to prevent further
tissue damage (reducing the concentration of the circu-
lating precursor protein, stabilising its native structure or
interfering with the aggregation of misfolded prefibrillar
forms) (fig. 3). Reabsorption of existing amyloid deposits
is another potential therapeutic approach [77]. Im-
munotherapy has been investigated in the past decade us-
ing an anti-SAP (anti-serum amyloid P) antibody that tar-
gets a common constituent of all amyloid deposits.
However, despite encouraging preliminary results, this ap-
proach has not completed phase III clinical development
[78]. Doxycycline is currently the only investigational
drug potentially active on different types of amyloidosis
based on its in vitro and in vivo efficacy to disrupt fibrils of
various type [79, 80].
During the last decade, different phase III randomised tri-
als reported the efficacy and safety of treatments prevent-
ing or delaying ATTR amyloidosis progression. As a re-
sult, patients’ quality of life and survival have significantly
improved [81–85].
Treatments targeting different steps of the amyloidogenic
cascade have been developed (fig. 3). The gene-silencing
agents patisiran and inotersen suppress the synthesis of he-
patic TTR [81, 82], whereas small-molecule ligands, such
as tafamidis, stabilise the TTR tetramer, preventing dis-
sociation into amyloidogenic monomeric forms [84]. Al-
though not registered for this indication, the clinical effica-
cy of diflunisal as a TTR stabilszer has been demonstrated
in a phase III study [83].
Liver transplantation
Liver transplantation was the first effective treatment for
ATTRv amyloidosis. It halts the production of variant
TTR, with production of wild-type TTR by the donor liver.
Liver transplantation was demonstrated to stop progression
of the neuropathy after a mean follow-up of 4 years in
patients with p.V50M at an early stage [86]. Worldwide,
more than 2000 patients with ATTRv amyloidosis under-
went liver transplantation [87]. Long-term follow-up data
reported doubling of the survival time for patients with ear-
ly-onset ATTR p.V50M amyloidosis at initial stages; the
impact of on survival in late-onset p.V50M or other vari-
ants is not clear, even when combined liver-heart trans-
plantation is considered [88].
Nevertheless, ATTR amyloidosis can progress after liver
transplantation, as wild-type TTR tends to accumulate on
pre-existing amyloid deposits [89, 90], and because the
production of mutant TTR in the choroid plexus ependy-
mal cells of the brain and retinal epithelium in the eye
persists. Long-term manifestations in transplanted patients
include: progressive ocular damage leading to glaucoma
and visual loss and central nervous system manifestations
typically consisting of transient ischaemic attack (TIA)-
like episodes, stroke or seizures due to extensive cerebral
amyloid angiopathy [91]. Patients with ATTRv amyloido-
sis and ultimately die from progressive neuropathy, car-
diac amyloidosis or stroke [92].
Disease-modifying drugs
Tafamidis
Tafamidis meglumine, an analogue of thyroxine, can sta-
bilise both wild-type and fibrillogenic variants of TTR, in-
hibiting tetramer dissociation, which is the rate-limiting
step in the amyloidogenic process [84]. This effect slows
ATTR amyloidosis progression. Tafamidis is administered
orally. Its safety and efficacy in slowing polyneuropathy
progression in early-stage p.V50M were demonstrated in
an 18-month randomised, placebo-controlled trial followed
Figure 3: Current and investigational therapeutic strategies for transthyretin amyloidosis. Therapeutic interventions target different steps in the
process of transthyretin amyloid formation.
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by two open-label extension studies [84]. Based on these
results, the drug was approved in Europe, Japan, Israel and
several countries in Latin America, but not in Switzerland,
for patients with isolated ATTR polyneuropathy. The re-
sults of long-term treatment indicate a sustained delay in
neurological deterioration, with earlier initiation associat-
ed with better outcomes [84, 93, 94]. Real-world data sup-
port a survival benefit in both early-onset and late-onset
p.V50M compared with historical controls and liver trans-
plantation patients [33].
Patients with cardiac ATTR amyloidosis were studied in
the randomised controlled ATTR-ACT trial, with 75% of
patients having ATTRwt amyloidosis and 25% having AT-
TRv amyloidosis [95]. In this trial tafamidis 80 mg,
tafamidis 20 mg or placebo were studied in a 2:1:2 ratio
for 30 months. The safety profile of tafamidis was similar
to placebo. The study was not powered to detect a possible
treatment effect in the subgroup of patients with ATTRv
amyloidosis, for whom an inferior outcome has been re-
ported [96]. Overall, the ATTR-ACT showed a benefit for
tafamidis-treated vs placebo-treated patients regarding a
hierarchically assessed primary endpoint of all-cause mor-
tality, followed by frequency of cardiovascular-related hos-
pitalisations [95]. Based on these results, tafamidis free
acid was recently approved by the US Food and Drug Ad-
ministration (FDA), and the European Medicines Agency
(EMA) for the treatment of cardiac ATTRwt amyloidosis
and cardiac ATTRv amyloidosis, at the dose 61 mg/day,
according to bioequivalence with tafamidis meglumine 80
mg [97]. Tafamidis has received marketing authorisation
for cardiac ATTR amyloidosis, but is not yet reimbursed,
in Switzerland.
TTR gene silencing
The gene silencing strategy halts the hepatic production of
TTR either by means of RNA interference (RNAi) or with
antisense oligonucleotides.
Patisiran, an RNAi agent, lowers the production of mutant
and wild-type TTR by targeting the 3′ untranslated region
of TTR mRNA. In the APOLLO trial, 225 patients with
polyneuropathy (stage I or II) were randomised to receive
patisiran at 0.3 mg/kg i.v. every 3 weeks or placebo for 18
months [81]. The mean modified neuropathy impairment
score (NIS) + 7 (mNIS+7), improved in patisiran-treated
patients compared with baseline by –6 points versus pro-
gression by +28 points in the placebo arm. Up to 56%
of patients improved their mNIS+7 score compared with
baseline and 51% their QoL [98]. Improvement in total
COMPASS-31 score and in individual domains orthostat-
ic intolerance and gastrointestinal symptoms was observed
[99]. Most frequent AEs were infusion related reactions or
oedema, with an overall good safety profile. In the pre-
specified cardiac subpopulation, patisiran decreased mean
left ventricular wall thickness, global longitudinal strain
and NT-proBNP levels compared with placebo, suggesting
a beneficial effect on cardiac involvement [100].
Inotersen is a second-generation antisense oligonucleotide
that degrades both mutant and wild-type TTR mRNA, de-
creasing median serum TTR concentration by ̴ ~75%. Its
safety and efficacy were demonstrated in a multicentre,
randomised trial, in which patients with ATTRv polyneu-
ropathy (stage I and II) received either inotersen 300 mg/
week s.c. injection or placebo for 15 months [82]. In-
otersen significantly improved the two co-primary end-
points, progression of mNIS+7 and Norfolk-QOL, com-
pared with placebo at 15 months [101]. A rare risk for
thrombocytopenia and glomerulonephritis was reported.
Both inotersen and patisiran obtained marketing autho-
risation by the EMA and FDA in ATTRv amyloidosis
with polyneuropathy stage I and II. Only patisiran obtained
marketing authorisation by Swissmedic and is reimbursed
based on detailed criteria defined by the Swiss FOPH. Vi-
tamin A supplementation is needed to prevent potential
risks of eye damage due to drug-related reduced levels of
the vitamin.
Diflunisal
Diflunisal is a nonsteroidal anti-inflammatory drug which
binds within the two thyroxine binding sites of TTR [102].
In a phase III, randomised, placebo-controlled trial of pa-
tients with ATTRv polyneuropathy resulting from a diverse
number of mutations, diflunisal (250 mg orally twice dai-
ly) was well tolerated [83]. Diflunisal is not available in
Switzerland, and the Cantonal Pharmacy has to be in-
formed prior to its use. Patients who agree to a "compas-
sionate use" of diflunisal, can order the drug via an inter-
national pharmacy.
Doxycycline
The combination of doxycycline and tauroursodeoxycholic
acid was evaluated in a phase II trial enrolling 20 patients
(3 patients having ATTRwt amyloidosis). No progression
of cardiac or neurological involvement was noted [103,
104].
Gene editing and/or seeding inhibitors
CRISPR/Cas9 technology is in pre-clinical development
to silence expression of TTR, as are TTR fibril capping
agents [105].
Supportive therapy
Supportive treatment is extremely important in the man-
agement of all patients with amyloidosis and is discussed
in more detail in the chapter on ATTRwt amyloidosis (see
section 3.4.2.).
Follow-up
Clinical and biological follow-up in specialised centres
every 3–6 months is recommended, including a compre-
hensive follow-up with disability and QOL questionnaires,
and a standardised cardiological and neurological work-
up (table 5) [I, C]. A standardised ophthalmological as-
sessment should be performed every 1–2 years [I, C]. SAN
recommends that the lead for patient follow-up should be
cardiological for patients with predominantly cardiac
manifestations and neurological for patients with predom-
inantly neurological manifestations [I, C]. In Switzerland,
for regulatory reasons, patients treated with patisiran must
have a yearly assessment in a reference centre for amyloi-
dosis (CHUV, Lausanne / University Hospital Zurich) to
evaluate treatment continuation.
Patients with confirmed diagnoses should be regularly
monitored for disease progression by an interdisciplinary
team. Self-administered questionnaires are important out-
come measures. Assessments should be scheduled every
3–6 months in patients with advanced-stage cardiac or neu-
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rological disease, and every 6 months in patients with ear-
ly-stage disease.
Wild-type transthyretin amyloidosis (ATTRwt)
Diagnosis
ATTRwt amyloidosis is a disease of the elderly, with a me-
dian age at diagnosis of 74 years. It is rarely diagnosed in
the 40s–60s [106, 107]. Cardiac involvement by ATTRwt
amyloidosis is mainly responsible for the clinical presen-
tation, but soft tissue involvement is also common, mani-
festing as bilateral carpal tunnel syndrome, stenosis of the
lumbar spine, and/or spontaneous biceps tendon rupture
[24, 105, 108–110]. Neuropathy can be detected in up to
10% of patients, though few cases with significant periph-
eral and/or autonomic neuropathy are reported [107].
Endomyocardial biopsy is the gold standard for cardiac
ATTR amyloidosis diagnosis and is nearly 100% sensitive
and specific if biopsy specimens are collected from mul-
tiple sites (at least four are recommended) and tested for
amyloid deposits by Congo red staining [111]. Methods
for the identification of the precursor protein are immuno-
histochemistry (in experienced pathology laboratories) or
laser dissection, and tandem mass spectrometry analysis
[112]. Endomyocardial biopsy specimens are usually ob-
tained via a femoral or internal jugular venous approach
from the right ventricular septum, which has the advantage
of posing a low risk of cardiac perforation. The overall risk
of major complications is relatively low in experienced
hands ( ~1%) [113].
Non-biopsy diagnostic approach
In the absence of monoclonal gammopathy, scintigraphy
using bone-avid radiotracers can accurately diagnose AT-
TR amyloidosis with cardiac involvement, without the
need for biopsies. Three technetium-labeled radiotracers
have been evaluated for ATTR amyloidosis identification.
These include 99mTc-pyrophosphate (available in the Unit-
ed States), 99mTc-3,3-diphosphono-1,2-propanodicar-
boxylic acid (DPD) or 99mTc hydroxymethylenediphospho-
nate (HMDP), [113], the latter two being available in
Europe.
The mechanisms of myocardial retention of these bone-
avid tracers are not fully understood, but have been linked
to the presence of microcalcifications that are more com-
mon in ATTR amyloidosis than in AL amyloidosis [114,
115]. The results of an international collaboration with
a large cohort of endomyocardial biopsy-proven cases of
ATTRwt amyloidosis with cardiac involvement report a
100% specificity for ATTRwt amyloidosis when semi-
quantitative Perugini grade 2 or 3 uptake of these tracers
(fig. 4) was seen in the absence of a monoclonal gammopa-
thy by serum and urine testing in patients with heart fail-
ure and echocardiographic or magnetic resonance findings
typical of amyloidosis [116].
A non-biopsy diagnostic approach is recognised as part of
the diagnostic algorithm for patients with suspicted of AT-
TRwt amyloidosis. Scintigraphy alone cannot ensure a di-
agnosis with 100% specificity in patients with a concurrent
monoclonal gammopathy (monoclonal immunoglobulin
and/or free monoclonal immunoglobulin light chain) (fig.
5) [117].
Initial work-up
Personal and family history
The diagnosis of ATTRwt amyloidosis should be suspected
in older persons with HFpEF, or in patients with otherwise
unexplained elevated troponin levels and/or high levels of
NT-proBNP. ATTRwt amyloidosis should also be exclud-
ed in patients with left ventricular hypertrophy and a con-
comitant atrioventricular block [6]. Personal history of pre-
vious lumbar spinal stenosis, carpal tunnel syndrome and
spontaneous biceps tendon rupture may also raise suspi-
cions of ATTRwt amyloidosis (see above).
In contrast, a family history of progressive neuropathy and
heart failure at early stage should raise suspicion of ATTRv
amyloidosis.
Laboratory testing
Interdisciplinary discussion of the results obtained during
the screening for monoclonal gammopathy with specialists
in haemato-oncology should be considered [ IIa, C].
The following screening panel for monoclonal gammopa-
thy should be considered: serum protein electrophoresis,
serum immunofixation, serum free light chain measure-
ment and urine immunofixation [IIa, B].
Elevation of serum troponin and NT-proBNP levels are
often seen in ATTRwt amyloidosis, even in the absence
of a severe cardiomyopathy or symptoms of heart failure
[118]. An initial blood test should include complete blood
count, creatinine, creatinine clearance, eGFR, liver values
including alkaline phosphatase, NT-proBNP, troponin T,
microalbuminuria, proteinuria, serum free light chains, and
serum and urine protein electrophoresis with immunofixa-
tion. The evaluation of the presence of a monoclonal pro-
tein should be done by physicians with experience in the
field.
If a monoclonal protein is detected, assessments should in-
clude amyloid typing on a tissue biopsy from a clinically
affected organ endomyocardial biopsyif the heart is clini-
cally affected], or the abdominal fat pad, the rectum and
the salivary gland as surrogate organs.
Genetic testing
TTR genetic testing should be considered in all patients
with cardiac ATTR amyloidosis regardless of their age
[IIa, C]. The results have significant implications for fam-
ily members at risk (see section 2.2.3).
Neurological work-up
A visit to a neurologist may be considered at baseline for
patients with ATTRwt amyloidosis and neuropathy [IIb,
C].
Cardiological work-up
A cardiological work-up is recommended at baseline, in-
cluding ECG, 24-hour ECG, blood pressure and a TTE.
The need for bone scintigraphy, cardiac MRI and myocar-
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dial biopsy should be discussed by an interdisciplinary
team on a case-to-case basis [I, B].
Electrocardiography
A discrepancy between left ventricular wall thickness and
QRS voltages (low voltage) on a 12-lead ECG is com-
monly seen in cardiac amyloidosis [119], progressing to
low-voltage and a pseudo-infarction pattern at later disease
stages [120]. Atrioventricular block is another suggestive
feature of ATTRwt amyloidosis and may be seen in up to
20% of patients with cardiac amyloidosis [121]. Cardiac
conduction abnormalities may be the first manifestation of
ATTRwt amyloidosis, and amyloid infiltration of the sinus
and atrioventricular nodes may prompt pacemaker implan-
tation.
Echocardiography
Echocardiography is the most important tool for the di-
agnosis of cardiac amyloidosis. Amyloid deposits lead to
a progressive thickening of the left- and right ventricular
walls. This thickening typically presents with an increased
echogenicity and a granular sparkling appearance [122].
Amyloid deposits may also be seen as a thickening of the
atrioventricular valves and of the inter-atrial septum. Dur-
ing early stages of disease, systolic function is preserved in
most patients, but progressive diastolic dysfunction is ob-
served. At later stages, severe diastolic dysfunction with a
restrictive filling pattern is typically associated with dilated
atria due to the chronically elevated left-sided filling pres-
sures [122]. Systolic dysfunction is a sign of advanced dis-
ease.
Characteristic of amyloidosis is an impaired global longi-
tudinal peak strain in speckle tracking analysis, with a gra-
dient from the apex to the base – with almost normal func-
tion at the apex (apical sparing) [123]. Pericardial effusion
is present in most cases.
Endomyocardial biopsy
Endomyocardial biopsy is the gold standard for diagnosing
cardiac amyloidosis but is an invasive procedure and not
always required to establish the diagnosis. See figure 5 for
a non-biopsy diagnosis approach. The biopsy must be as-
sessed by a pathologist with experience in the field.
Cardiac MRI
CMR is highly sensitive and specific for the assessment
of cardiac amyloidosis. CMR offers the gold standard for
structural and functional assessment combined with tissue
characterisation using T1 mapping and late gadolinium en-
hancement.The sensitivity (80–100%) and specificity
(8094%) are high for the detection of amyloidosis in pa-
tients with suspected infiltrative disease [62, 124]. Late
gadolinium enhancement and quantitative parametric map-
ping techniques such as prolonged T1 mapping times and
extracellular volume measurements are used for diagnosis
and prognosis assessment [125127].
Bone scintigraphy
Figure 4: Tc-DPD myocardial scintigraphy whole-body planar images. From left to right grade 0, grade 1, grade 2 and grade 3 myocardial up-
take are shown. (Image courtesy PD Dr. Aju P. Pazhenkottil, Cardiac Imaging, Department of Nuclear Medicine, University Hospital of Zurich,
Switzerland).
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Radionuclide imaging plays a distinctive role in the non-
invasive diagnosis of cardiac amyloidosis. High sensitivity
and specificity for ATTR amyloid deposits has been
proven for 99mTc-DPD and 99mTc-HMDP tracers. A Perug-
ini score of 2 or more, indicating a cardiac uptake equal to
or greater than rib uptake, is a widely accepted criterion for
defining the presence of cardiac TTR amyloid deposits, in
the absence of a monoclonal gammopathy (see above) [68,
114, 128]. Cardiac scintigraphy may be helpful for early
identification of affected individuals before the occurrence
of cardiac involvement assessed by other diagnostic tech-
niques (increased wall thickness) [129–132].
This technique is currently extensively applied; however,
important limitations have to be taken into account [133].
Cardiac positron emission tomography
Cardiac poisitron emission tomography (PET) using the
amyloid tracers 18F-florbetapir, 18F-florbetaben, or 11C-
Pittsburgh B compound, is accurate in diagnosing cardiac
involvement with a target to background (left ventricular
myocardium to blood pool) ratio >1.5 or a retention index
>0.030/min being typical features [134].
The cost of using of amyloid PET tracers for the diagnosis
of cardiac amyloidosis is not currently covered by health
insurance in Switzerland and a general diagnostic strategy
using these is therefore not recommended by the SAN con-
sensus.
Biopsy/pathology
The abdominal fat pad aspirate has a low sensitivity for 
ATTRwt amyloidosis (12–15%) [50, 135]. If biopsy 
proof of ATTR is required, but endomyocardial biopsy is 
not fea-sible, biopsies from surrogate sites such as the 
rectum or the salivary glands should be obtained.
Initial staging and risk stratification
Initial staging of all patients with ATTRwt amyloidosis
should be considered [IIa, B].
Gilmore et al. proposed a staging system that is applicable
to both ATTRwt and ATTRv cardiac amyloidosis, using
two simple and universally measured serum biomarkers:
NT-pro BNP and eGFR (see table 7) [71]. The staging sys-
tem discriminates between the ̴ ~20% patients with cardiac
ATTR amyloidosis who have a median survival of approx-
imately 2 years, the ̴ ~40% who have a median survival of
about 4 years, and the ̴ ~40% who have a median survival
of around 6 years [71]. Initial risk stratification should also
include functional NYHA class (table 8), which seems to
be predictive for treatment response [95]. Two other com-
monly used staging systems are based on the cardiac mark-
ers NT-proBNP and troponin T, or diuretic dose and NY-
HA functional class, respectively [73, 136].
Treatment
SAN recommends treatment guided by experienced centres,
using a multidisciplinary approach (cardiology, haemato-
oncology, neurology, nephrology, gastroenterology) [I, C].
Treatment with tafamidis 61 mg should be considered for 
patients with cardiac ATTRwt amyloidosis and dyspnoea 
NYHA class I-–III [IIa, B].
Case-by-case discussions should be considered prior to
tafamidis initiation for patients with significant comorbidi-
ties that interfere with intermediate-term survival [IIa, C].
Case-by-case discussions should be considered for pa-
tients with complex cardiac situations (e.g., concomitant
aortic stenosis, concomitant severe coronary artery dis-
ease), patients with a formal indication for implantation
Figure 5: Simplified diagnostic algorithm for patients with suspected cardiac amyloidosis.
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of an internal cardioverter defibrillator, and patients with
typical angina due to microvascular disease [IIa, C].
The optimal timing to start treatment for ATTRwt amy-
loidosis remains unclear, though it is known that there is
a long latency period before organ damage manifests. Pa-
tients treated at earlier stages of the disease are reported to
have a greater survival benefit [95].
Cardiac disease monitoring relies on NYHA class, labora-
tory testing (cardiac biomarkers NT-proBNP, BNP and tro-
ponin), functional testing (6-minute walking test or stress
test) and cardiac imaging (echocardiography, CMR).
Disease-modifying treatment
Tafamidis
The ATTR-ACT phaseIII clinical trial assessed tafamidis
20 mg versus tafamidis 80 mg versus placebo in wild-
type and hereditary ATTR cardiomyopathy [95]. A total
of 441 patients were enrolled for 30 months. Primary out-
come measurement was a combined endpoint of all-cause
mortality and cardiovascular-related hospitalisations [95].
Tafamidis was associated with lower all-cause mortality
and a lower rate of cardiovascular-related hospitalisations,
when compared with placebo. As anticipated above, this
benefit was observed mainly in the subgroup of patients
with NYHA class I and II, but not in the subgroup of pa-
tients with NYHA class III. The safety profile of tafamidis
was similar to placebo. Based on these results, tafamidis
free acid was approved by the FDA and EMA for the treat-
ment of cardiac ATTRwt amyloidosis and cardiac ATTRv
amyloidosis at the dose 61 mg/day, according to bioequiv-
alence with tafamidis meglumine 80 mg [97]. Tafamidis
free acid has received marketing authorisation in Switzer-
land for the treatment of transthyretin amyloidosis in adult
patients with wild-type or hereditary cardiomyopathy, but
is not yet reimbursed. A reimbursement request has to be
approved by the healthcare insurance prior to treatment ini-
tiation. The requests are currently evaluated according to
article 71b KVV.
TTR gene silencing
Patisiran and inotersen have not yet been extensively stud-
ied in patients with ATTRwt amyloidosis. The effect of
patisiran in patients with cardiac ATTR amyloidosis in-
cluding both wild-type and variant subtypes is being eval-
uated in an ongoing phase III trial (APOLLO-B,
NCT03997383). Accrual has been completed and first re-
sults are expected in mid-2022. Vutrisiran, a subcutaneous-
ly administered investigational RNAi therapeutic, is cur-
rently being studied in a large phase III trial (HELIOS-B,
NCT04153149) [137].
Doxycycline
The combination of doxycycline and tauroursodeoxycholic
acid was evaluated in a phase II trial enrolling 20 patients
(3 patients having ATTRwt amyloidosis) [103, 104]. No
progression of cardiac or neurological involvement was
reported. The combination of doxycycline and taurour-
sodeoxycholic acid is currently being studied in a single-
centre phase III trial (NCT03481972).
Diflunisal
The experience with diflunisal in ATTR cardiomyopathy
has been limited to open-label, single-centre studies. Diflu-
nisal (250 mg orally twice daily) was generally well toler-
ated, with adverse effects in a minority of subjects, includ-
ing thrombocytopenia and renal dysfunction. Diflunisal
was associated with a survival benefit similar to tafamidis
in one nonrandomised ATTRwt amyloidosis study [138].
Despite its application in patients with concomitant use of
oral anticoagulants, significant bleeding has not been re-
ported, but patients were highly selected in this study. The
lower toxicity could be related to the reduced dosage of di-
flunisal administered for TTR stabilisation, which is low-
er than the dose indicated as an anti-inflammatory drug
[139]. Diflunisal can be considered for selected patients
with ATTRwt amyloidosis without severe renal dysfunc-
tion (eGFR >45 ml/min/1.73m2), with normal platelet
function and count, no volume overload and without recent
haemodynamic instability. A proton pump inhibitor might
be added and kidney function should be regularly moni-
tored. Diflunisal is not available in Switzerland, and the
Cantonal Pharmacy has to be informed prior to its use. Pa-
tients who agree to a "compassionate use" of diflunisal can
order the drug via an international pharmacy.
Supportive measures
The key objective of ATTRwt amyloidosis supportive
management is to maintain a stable fluid balance. To
achieve euvolaemia, sodium and fluid restriction and per-
sonalised diuretic therapy are central for patients with
symptomatic HFpEF. On the other hand, excessive diuretic
treatment can cause symptomatic hypotension and worsen-
ing of renal perfusion. Due to their bioavailability, loop di-
uretics (torasemide and furosemide) are favoured, and may
be combined with aldosterone receptor antagonists or thi-
azide diuretics. Serum potassium levels should be moni-
tored regularly [140).
When adjusting antihypertensive treatment, clinicians
should be aware that calcium channel blockers (verapamil
type only) can cause high degree heart block and beta-
blockers may not be well tolerated (because of a fixed
stroke volume – cardiac output depends solely on heart
rate) [141].
Compression stockings and midodrine may be useful in ad-
vanced stages with arterial hypotension, when cardiorenal
syndrome can also occur [141].
In atrial fibrillation, tachycardia and bradycardia may not
be well tolerated. Data on the outcome of catheter ablation
in ATTR amyloidosis are limited. Antiarrhythmic treat-
ment (amiodarone) and cardioversion can be offered once
intracardiac thrombi have been excluded, independent of
the presence of an active and therapeutic anticoagulation
[141, 142]. In the case of atrial fibrillation, long-term an-
ticoagulation is recommended regardless of the CHADs-
VASc score [141].
Patients with syncope, pre-syncope or palpitations should
undergo a 24-hour ECG assessment. A 24-hour ECG
should be recorded every 6–12 months to screen for atrial
fibrillation and conduction disturbances. Indications for
permanent pacing should follow the European Society of
Cardiology guidelines [143].
For gastric and bowel disease, symptomatic treatment
should follow that of a gastroparesis of other causes (hy-
gienic measures such as smoking cessation, avoidance of
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alcohol and sparkling drinks, meal splitting). Metoclo-
pramide, domperidone and erythromycin can be adminis-
tered in the case of no response. To limit constipation, a fi-
bre-rich diet and osmotic laxatives can be prescribed [144,
145].
Physiotherapy can be beneficial for patients with cardiac
ATTR amyloidosis, especially for patients with concomi-
tant gait disorder (stenosis of the lumbar spine) or patients
at high risk for falls.
Cardiac transplantation
Although heart transplantation is not a viable option for
most patients with ATTR cardiopathy because of advanced
age, younger patients with predominantly cardiac involve-
ment should be referred to a transplant centre in good time.
In the current International Society of Heart/Lung Trans-
plantation guidelines, heart transplant in cardiac amyloido-
sis may be considered on an individual basis after multi-
disciplinary assessment [146, 147]. Outcomes in carefully
selected patients are similar to those of patients transplant-
ed for other causes of heart failure [148].
Follow-up
Cardiological follow-up should be considered every
3–6 months, including clinical and laboratory evaluation
(NT-proBNP, troponin T, creatinine, proteinuria, albumin-
uria), and a comprehensive evaluation including ECG,
24-hour ECG, TTE every 6–12 months, ergometry, depend-
ing on disease severity and treatment [IIa, C]. Regular
blood pressure and body weight home monitoring may be
considered in order to adapt diuretic dose targeting eu-
volaemia [IIb, C].
Patients at risk for developing systemic ATTR
amyloidosis
Asymptomatic carriers of amyloidogenic mutations
The increasing availability of effective and early treat-
ments led to the promotion of pre-symptomatic testing for
hereditary TTR amyloidosis [52–55] (see section2.2.3).
The screening of asymptomatic carriers of amyloidogenic
mutations should be individualised based on patient prefer-
ences and the predicted age at disease onset. Based on the
specific TTR mutation and the onset age in other affected
family members, the predicted age at disease onset can be
estimated. Systemic monitoring of asymptomatic carriers
should be considered at least 10 years prior to the predict-
ed age at disease onset [149, 150] [IIa, C].
Domino liver transplant recipients
For patients who received an organ from a liver-transplant
donor with ATTRv amyloidosis, a baseline evaluation of
cardiac function (ECG, TTE), renal function screening
(eGFR, proteinuria), and a neurological assessment includ-
ing laboratory testing for peripheral neuropathy and a
nerve conduction study are mandatory. A 6-monthly or
yearly follow-up for signs of neuropathy (including BMI,
autonomic dysfunction) should be considered [IIa, B].
Prospective data on the development of de novo neuropa-
thy in domino liver recipients related to mutant TTR report
a rate of 25% [151]. In this setting, polyneuropathy can de-
velop within years after liver tarnsplantation and is a rapid-
ly progressive disease. Advanced age of the recipient is a
known risk factor.
Patients with transthyretin amyloid in tissue biopsy
No guidelines are available regarding follow-up in this
setting. A baseline evaluation for patients in whom ATTR
has been detected in biopsies obtained from the yellow
ligament, from muscle tendons or from the carpal tunnel,
is recommended. A cardiac work-up including ECG, TTE
(including speckle-tracking echocardiography based left
ventricular strain analysis) and genetic testing for ATTRv
amyloidosis should be considered [IIa, C]. The necessity
for further investigations with bone scintigraphy and CMR
should be discussed on a case-to-case basis. An ongoing
Swiss study (NCT03966105), is investigating the preva-
lence of ATTR amyloidosis in patients undergoing surgery
for carpal tunnel syndrome or stenosis of the lumbar spine.
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